Objective:

To report a case of a child with high-risk acute lymphoblastic leukemia (ALL) who received blinatumomab combined with prophylactic donor lymphocyte infusion (DLI) to prevent relapse after allogeneic hematopoietic stem cell transplantation (HSCT).

Approach:

Key Findings:

• The child developed grade 1 cytokine release syndrome (CRS) during treatment but did not experience severe adverse reactions.
• Sequential blinatumomab plus prophylactic DLI was well-tolerated and maintained sustained remission after HSCT.

Interpretation:

Limitations:

• The findings are based on a single case report.
• Larger prospective trials are needed to verify safety, efficacy, and optimal dosing.

Conclusion:

Further investigation is warranted to assess the safety and efficacy of the combined regimen of blinatumomab and DLI for preventing relapse in high-risk pediatric ALL.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.